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Abstract While much is known about the beneficial effects of 
myocardial stress adaptation, relatively less information is 
available about the adaptive mechanisms. To explore the 
signaling pathways of stress adaptation, isolated working rat 
hearts were divided into three groups. Group I was adapted to 
stress by conventional technique of repeated ischemia and 
reperfusion consisting of 5 min of isehemia followed by 10 rain 
of reperfusion, repeated four times. Group II was treated with 
100 pM of genistein, a tyrosine kinase inhibitor, followed by 
preconditioning as described for group I. The third group, 
perfosed with buffer only for 60 rain, served as control. All hearts 
were subjected to 30 min of ischemia followed by 30 min of 
reperfusion. The results of our study demonstrated better 
postiscbemic myocardial functions in the preconditioned hearts 
as evidenced by increased aortic flow, coronary flow, developed 
pressure and lesser amount of tissue injury as evidenced by the 
decreased creatine kinase release. The preconditioning effects 
were associated with enhancement of phospholipase D activity in 
the heart. The preconditioning effect was almost abolished by the 
genistein treatment which also prevented the enhancement of 
phospholipase D activities. Additionally, preconditioning of the 
rat hearts stimulated protein kinase C, MAP kinase, and 
MAPKAP kinase 2 activities which were inhibited by genistein. 
The results identifies for the first time tyrosine kinase- 
phospholipase D as potential signaling pathway for isehemic 
preconditioning, and implicates the involvement of multiple 
protein kinases in myocardial adaptation to ischemia. 
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1. Introduction 
Myocardial adaptation to ischemic stress, which is the man- 
ifestation of the earlier stress response that occurs during re- 
peated episodes of brief ischemia nd reperfusion, can render 
the myocardium ore tolerant o a subsequent potentially 
lethal ischemic injury [1]. This transient adaptive response 
has been demonstrated to be associated with decreased reper- 
fusion-induced arrhythmias [2], increased recovery of postis- 
chemic contraction functions [3], and reduction of the infarct 
size [4]. The adaptive protection has been found to be 
mediated by gene expression and their transcriptional regula- 
tion [5]. It has been demonstrated that cellular protein kinase 
C (PKC) activation is an important step in the mechanism of 
adaptive protection of the heart [6]. However, the intracellular 
signaling events, which mediate stress responses of the myo- 
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cardium, are not fully understood yet. Recently, many studies 
have indicated that mitogen-activated protein (MAP) kinases, 
a novel serine/threonine protein kinase family, play an essen- 
tial role in mediating intracellular signal transduction events 
[7,8]. In response to extracellular stimulation, MAP kinases 
are rapidly activated and in turn regulate cellular functions by 
inducing the phosphorylation of proteins, such as an onco- 
gene product c-jun, $6 ribosomal protein kinase, and MAP 
kinase activated protein (MAPKAP) kinase 2 [9,10]. MAP- 
KAP kinase 2 has been implicated in a novel mammalian 
stress activated signal transduction pathway initiated by a 
variety of mitogens, pro-inflammatory c tokines, or environ- 
mental stresses, where it regulates its substrate molecules by 
serine/threonine phosphorylation [11,12]. Stimulation of cul- 
tured cardiomyocytes with A1 selective adrenergic analogues, 
endothelin 1, fibroblast growth factors, and mechanical stress 
activates the MAP kinase signaling cascade [13]. In addition, 
our previous tudies indicate that environmental stresses, in- 
cluding heat shock and oxidative stress, and phorbol ester 
treatment of cultured cardiac myoblast cells resulted in a rap- 
id increase in cellular MAPKAP kinase 2 activity (Zu, Ai, 
Gilchrist, Sha'afi, Das and Huang, personal communication). 
To understand signaling events that mediate in vivo the is- 
chemic response of the myocardium, changes in enzymatic 
activities of tissue MAP kinases and MAPKAP kinase 2 de- 
rived from ischemic preconditioning-treated h arts were de- 
tected. Effects of tyrosine protein kinases on the activation 
of the myocardial MAP kinases/MAPKAP kinase 2 cascade 
were examined using a specific kinase inhibitor. Moreover, 
changes in myocardial phospholipase D activity in response 
to ischemic preconditioning were determined. 
2. Materials and methods 
2.1. Isolated perfused rat heart preparation and experimental protocol 
Sprague-Dawley male rats of approximately 350 g body weight 
were anesthetized with intraperitoneal pentobarbital (80 mg/kg). After 
intravenous administration of heparin (500 IU/kg), the chests were 
opened, and the hearts were rapidly excised and mounted on a non- 
recirculating Langendorff perfusion apparatus. Retrograde perfusion 
was established ata pressure of 100 cm H20 with oxygenated nor- 
mothermic Krebs-Henseleit bicarbonate (KHB) buffer with the fol- 
lowing ion concentrations (inmM): 118.0 NaC1, 24.0 NaHCO3, 4.7 
KC1, 1.2 KH2PO4, 1.2 MgSO4, 1.7 CaCI2, and 10.0 glucose. The 
KHB buffer had been previously equilibrated with 95% O215% CO2, 
pH 7.4 at 37°C. The hearts were preconditioned bysubjecting them to 
5 min ischemia by terminating the coronary flow followed by 10 min 
of reperfusion. The process was repeated four times [14]. The pulmo- 
nary vein was then cannulated and the Langendorff perfusion discon- 
tinued for subsequent working heart perfusion as described previously 
[15]. It was essentially a left-heart preparation i  which oxygenated 
KHB at 37°C enters the cannulated pulmonary vein and left atrium at 
All rights reserved. 
234 
a filling pressure of 17 cm H20. The perfusion fluid then passes to the 
left ventricle from which it is spontaneously ejected through the aortic 
cannula against a pressure of 100 cm H20. The working hearts were 
perfused for 5 min for stabilization. Normothermic ischemia was in- 
duced for 30 min by terminating the left atrial flow which was fol- 
lowed by 30 min of reperfusion. To examine the effects of myocardial 
tyrosine protein kinases on the preconditioning-induced kinase activa- 
tion, isolated rat hearts were perfused with 100 laM genistein (Sigma 
Chemical, St. Louis, MO), a specific tyrosine kinase inhibitor, supple- 
mented with KHB buffer for 10 min, while the control group was 
perfused with buffer alone. Control experiments were performed by 
perfusing the hearts in the presence and absence of 100/aM genistein 
for 60 min without ischemia nd reperfusion. The experiments were 
terminated prior to genistein treatment (baseline), after precondition- 
ing, and after ischemia nd reperfusion. Heart biopsies were frozen in 
liquid nitrogen for subsequent analysis of phospholipase D, protein 
kinase C, MAP kinases, and MAPKAP kinase 2. The release of crea- 
tine kinase (CK) was estimated in the perfusate buffer. 
To estimate phospholipase D activity, hearts were perfused with the 
buffer containing 250 mCi [1-a4C]butanol (NEN, Boston, MA; 4 mCi/ 
mmol) (final concentration of butanol was 20 mM) prior to any treat- 
ment and preconditioning [16]. Biopsies were frozen in liquid nitrogen 
for subsequent assay for [14C]phosphatidylbutanol. 
To examine the effects of genistein on myocardial functions, aortic 
flow and developed pressure were measured. The aortic flow was 
monitored using a calibrated rotameter while the developed pressure 
was determined as the difference between aortic end-systolic and aor- 
tic end-diastolic pressure measured through an on-line aortic pressure 
transducer. The data were recorded and analyzed in real time using 
the Cordat II data acquisition, analysis, and presentation system 
(Data Integrated Scientific Systems, Pinckney, MI; Triton Technolo- 
gies, Inc., San Diego, CA) [15]. 
Inhibition of tyrosine kinase by genistein was confirmed by treating 
the samples with SDS-PAGE followed by Western blotting using a 
monoclonal antiphosphotyrosine antibody (1 /ag/ml) obtained from 
Upstate Biotechnology Inc., Lake Placid, NY. 
2.2. Estimation of phospholipase D
The frozen biopsies were homogenized and extracted with chloro- 
form/methanol mixture [16]. Phospholipids were separated by thin 
layer chromatography on silica gel K6 plates using the organic phase 
of 2,2,4-trimethylpentane/ethyl acetate/acetic a id/H20 (6:11:2:9, v/v) 
as solvent. The phosphatidylbutanol band was identified by co-chro- 
matography of authentic standard. The band was scraped off into a 
tube and radioactivity quantitated using a liquid scintillation counter. 
2.3. Enzymatic assay of protein kinase C, MAP kinases, and 
MAPKAP kinase 2 
Approximately 0.3~).4 g of heart biopsy was placed in a measured 
volume of ice-cold Tris-sucrose buffer that contained 0.35 M sucrose, 
10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.5 mM DTT and 0.1 mM 
PMSF. The tissue was homogenized with a Polytron homogenizer, 
and the resulting homogenate was centrifuged at 15000xg for 20 
min. The supernatant was used for the estimation of MAP kinases 
and MAPKAP kinase 2. To estimate protein kinase C (PKC), hearts 
were homogenized in a buffer containing 20 mM Tris-HCl, 250 mM 
sucrose, 2 mM EGTA, 4.5 mM EDTA, 1 mM DTT, 1 mM PMSF, 
250 mg/ml trypsin inhibitor, 1 mM benzamidine, 0.005% leupeptin, 
pH 7.4. Homogenates were centrifuged at 14000×g for 20 min. The 
resulting supernatants are centrifuged again at 105 000 ×g for 90 min. 
The final supernatant was used as cytosolic fraction. The pellets from 
14000×g centrifugation were rehomogenized in the same buffer and 
centrifuged at 14000×g for 20 min. The pellets obtained were dis- 
carded. The supernatants were centrifuged again at 105 000 x g for 90 
min. The supernatants were discarded, and the pellets from the two 
105000×g centrifugations were combined and resuspended in a 
homogenizing buffer containing 0.3% Triton X-100 (v/v) using a 
hand-held homogenizer. This fraction was again centrifuged at 
105000×g for 45 min. This final supernatant serves as particulate 
fraction. Protein concentration was determined with a BCA protein 
assay kit (Pierce, Rockville, IL). 
To examine MAPKAP kinase 2, a synthetic peptide substrate de- 
rived from the glycogen synthase N-terminus (KKPLNRT- 
LSVASLPG-amide) was used [17]. The kinase assay was initiated by 
adding 15 /ag of supernatant protein to a 40/al reaction mixture con- 
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Fig. 1. Effects of preconditioning on tyrosine phosphorylation and 
its inhibition by genistein. Isolated hearts were preconditioned 
(4×PC) by repeated ischemia and reperfusion. Control hearts were 
perfused under identical conditions without preconditioning proto- 
col. Another group of hearts were preperfused with genistein prior 
to preconditioning. Hearts were immediately frozen after the experi- 
ments. Phosphorylation of tyrosine kinase was examined by treating 
the samples with SDS-PAGE followed by Western blotting using a 
monoclonal anti-phosphotyrosine antibody (1 /ag/ml). Results are 
representative of four experiments per group. Each experiment was 
repeated at least three times with identical results. Lane A: control; 
lane B: preconditioned; lane C: genistein followed by precondition- 
ing. 
taining 20 mM HEPES, pH 7.3, 10 mM MgC12, 1 mM EGTA, 5 [aM 
sodium ortho-vanadate, 5 /aM okadaic acid, 2 mM DTT, 40 /aM 
[7-32p]ATP (4.4× 103 cpm/pmol), and 40 /aM substrate peptide. The 
reaction was allowed to proceed for 10 min at 30°C. The amount of 
32p incorporation into the peptide was analyzed by a liquid scintilla- 
tion counter. MAP kinase activity was assessed using myelin basic 
protein as substrate under the same conditions as the MAPKAP ki- 
nase 2 assay [18]. For the protein kinase C assay, the resulting super- 
natant (solubilized membrane) and the cytosolic fractions were sub- 
jected to ion-exchange chromatography using DEAE columns (bed 
volume 2 ml). After application of the samples to the column by 
quantity, the columns were washed with 10 ml of the above buffer. 
PKC is eluted with the same buffer but with the inclusion of 400 mM 
NaC1. Protein concentration is measured in the elute using BCA re- 
agent from Pierce. PKC activity was determined according to the 
method described by Hannun et al. [19]. Aliquots containing 10-15 
/ag of total protein were used in the PKC reaction. The reaction 
mixture contains in a final volume of 100 /al: 50 mM Tris-HC1, pH 
7.5, 10 mM DTT, 15 mM Mg-acetate, 150 /aM ATP, 1 /aCi 
[~,-32p]ATP. Reactions are divided and carried out with 4 mM Ca 2+ 
and 1 /aM phorbol-12 myristate-13 acetate and 65/ag/ml L-ec-phospha- 
tidyl-L-serine (PS), PS only, and with 4 mM EDTA but no PS. 250- 
300/aM epidermal growth factor receptor peptide (EGFR) is used in 
our reactions as substrate (specific for PKC). Reactions were carried 
out at 25°C for 30 min and terminated by adding 100/al of 75 mM 
ortho-phosphoric acid. 150/al of this reaction mixture is spotted onto 
a P-81 phosphocellulose paper, washed with 75 mM orthophosphoric 
acid and radioactivity counted in a liquid scintillation counter. The 
specific activity is calculated by subtracting kinase activity in the pres- 
ence of 4 mM EDTA and no PS from Ca 2+ plus PS-stimulated kinase 
activity. 
3. Resu l ts  
3.1. Effects of  genistein on tyrosine kinase phosphorylation 
As shown in Fig. 1, tyrosine phosphory la t ion  was enhanced 
after precondit ioning.  Genistein b locked the phosphory la t ion  
o f  specific cellular proteins including 98 kDa,  80 kDa,  77 kDa,  
70 kDa,  40 kDa,  38 kDa,  25 kDa and 20 kDa proteins. 
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Fig. 2. Effects of preconditioning and genistein on phospholipase D 
in rat heart. Isolated rat hearts were preperfused with 100 BM 
genistein for 10 min prior to preconditioning by repeated ischemia 
and reperfusion. The control group did not receive any genistein. 
After preconditioning, hearts were subjected to 30 min of ischemia 
followed by 30 min of reperfusion. Results are expressed as means 
± S.E.M. of six animals per group. Each assay was run in duplicate. 
*P<0.05 compared to control; **P<0.05 compared to baseline 
control; ***P<0.05 compared to preconditioned group. White col- 
umns, control; dark-hatched columns, control+genistein; black col- 
umns, preconditioned; light-hatched columns, preconditioned+ge- 
nistein. 
3.2. Effects of  genistein on myocardial phospholipase D 
Phospholipase D activity was increased by 50% after is- 
chemic preconditioning (Fig. 2). The enzyme activity was 
further increased after 30 min of ischemia followed by 30 
min of reperfusion. Genistein had no effect on phospholipase 
D in the normal heart, but it inhibited the preconditioning 
and ischemia/reperfusion-mediated enhancement of the activ- 
ities. 
3.3. Effects of  genistein on protein C kinase, MAP kinase and 
MAPKAP kinase 
The activities of MAP kinase as well as MAPKAP kinase 
were enhanced significantly after preconditioning (Fig. 3). 
They were further activated after ischemia and reperfusion. 
The tyrosine kinase inhibitor, genistein, inhibited the activa- 
tion of kinases. After preconditioning PKC was translocated 
from the cytosol to the particulate fraction and stimulated by 
Table 1 
Effects of genistein on myocardial functions 
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113%. Genistein inhibited this translocation/activation by 42% 
(Fig. 3). After ischemia/reperfusion, PKC activity in the par- 
ticulate fraction of the control group was increased by 46% 
compared to the baseline value (Fig. 4). The preconditioned 
group showed a 35% increase in PKC activity after ischemia/ 
reperfusion. Genistein inhibited this increased activity by 77%. 
Genistein by itself had no effects on any of the kinase activ- 
ities. 
3.4. Effects of  genistein on postischemic myocardial 
performance 
We also studied the left ventricular performances of the 
normal hearts after preconditioning and ischemia/reperfusion, 
and compared the results with those of genistein-treated 
hearts. As shown in Table 1, heart rate was not affected by 
preconditioning or by ischemia/reperfusion. Genistein had no 
effect on the heart rate. DP, dp/dtm~, AF, CF - all remained 
unchanged after preconditioning. These parameters were sig- 
nificantly lowered after ischemia/reperfusion in both groups. 
However, the values were significantly higher compared to the 
non-preconditioned control group. The beneficial effects of 
preconditioning were completely abolished in genistein-treated 
hearts. The left ventricular functions of control hearts showed 
no effects after genistein treatment. 
4. Discussion 
This study demonstrates for the first time that ischemic 
preconditioning triggers protein tyrosine kinase activation of 
phospholipase D in rat heart, because preconditioning- 
mediated enhancement of phospholipase D was inhibited by 
the blocker of tyrosine kinase, genistein. Inhibition of tyrosine 
kinase by genistein also attenuated the activation of MAP 
kinases, MAPKAP kinase 2 and protein kinase C further 
suggesting for the first time the existence of a phospholipase 
D-mediated signaling pathway in the ischemic myocardium. 
The results supports our previous hypothesis that phospho- 
lipase D plays a major role in cell signaling in the ischemic 
heart [20]. Phospholipase D hydrolyzes the phosphate ester 
bond of the head group that converts the phospholipids, espe- 
cially phosphatidylcholine, into phosphatidic acid and free 
head group alcohol generating the second messenger, diacyl- 
glycerol. The intermediate compound, phosphatidic acid, may 
itself be a second messenger product, but its precise role in 
signal transduction is not known. Diacylglycerol serves as the 
major co-factor for the translocation and activation of protein 
kinase C. In turn, protein kinase C may trigger the MAP 
kinase pathway by activating MAP kinase kinase kinases 
(MAP KKK). 
Control Preconditioned Genistein 
Baseline I/R Baseline I/R Baseline I/R 
Heartrate 305±3.2 295±4.7 294±4.9 285±9.0 302±11.3 289±9.1 
DP 73±1.5 35.4±1.8 + 74±3.1 45.4±1.4" 74±0.8 37.3±3.5 
dp/dt .... 2983±74 1520±63 + 3064±111 2055±89* 2875±134 1650±120 
AF 43.5±0.9 14.4±0.7 + 44.0±0.9 24.3±1.2" 43.0±0.8 15.3±1.6 
CF 24.1±0.6 17.1±0.4 + 24.3±0.4 19.6±0.5' 23.4±0.5 17.8±0.5 
+P < 0.05 compared to baseline; *P < 0.05 compared to control. 
DP, developed pressure; dp/dt ...... maximum first derivative of developed pressure; AF, aortic flow; CF, coronary flow; I/R, after 30 min ischemia 
followed by 30 min reperfusion. 
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Fig. 3. Effects of preconditioning and genistein on MAP kinases 
and MAPKAP kiase 2 in rat heart. Isolated rat hearts were preper- 
fused with 100 gM genistein for 10 min prior to preconditioning by 
repeated ischemia and reperfusion. The control group did not re- 
ceive any genistein. After preconditioning, hearts were subjected to 
30 rain of ischemia followed by 30 rain of reperfusion. Results are 
expressed as means+S.E.M, of six animals per group. Each assay 
was run in duplicate. *P<0.05 compared to control; **P<0.05 
compared to baseline control; ***P<0.05 compared to precondi- 
tioned group. White columns, control; dark-hatched columns, con- 
trol+genistein; black columns, preconditioned; light-hatched col- 
umns, preconditioned + genistein. 
We have used genistein to inhibit tyrosine kinase activity. 
This fungicide has been found to inhibit several tyrosine ki- 
nases such as c-src and v-abl with negligible inhibitory effect 
towards serine/threonine kinases [21]. The results of our study 
thus suggest hat genistein inhibited protein kinase C, MAP 
kinases and MAPKAP kinase 2 activities through tyrosine 
kinase and secondary to the inhibition of phospholipase D
activity in the heart. However, any non-specific effects of gen- 
istein on rat heart cannot be precluded from this experiment. 
In this study, the detected enzymatic activity in the in vitro 
kinase assay using MBP as a substrate resulted from the acti- 
vation of the tissue Erk and/or p38 MAP kinases. In in vitro 
studies, both Erk and p38 MAP kinases can phosphorylate 
and activate MAPKAP kinase 2 [17,22]. To detect tissue/cel- 
lular MAPKAP kinase 2 activity, a synthetic peptide derived 
from the N-terminus of glycogen synthase [22] is widely used 
as a specific substrate in in vitro kinase assays. In the present 
study, 20 gM H-7 was utilized in the kinase assay to inhibit 
enzyme activities mediated through other cellular kinases, in- 
cluding cAMP-dependent protein kinase (K~ = 3.0 pM), pro- 
tein kinase C (Ki =6.0 gM), and protein kinase G (K~ = 5.8 
~tM). The specificity of the kinase assay using whole tissue 
lysate and the peptide substrate has already been demon- 
strated from the observations that induced MAPKAP kinase 
2 activity, detected using the in vitro kinase assay with whole 
tissue lysates and synthetic peptide as substrate, was inhibited 
by the presence of the competitive inhibitory peptide for 
MAPKAP kinase 2 [23]. The MAP kinase activity thus truly 
reflects the total MAP kinase activity irrespective of whether it 
is derived from ERK,  JNK  or p38 MAP kinases. It should be 
noted that a recent study demonstrated that p38 MAP kinase, 
and not ERK MAP kinase, leads to the activation of MAP- 
KAP kinase 2 in vivo [24]. 
A growing body of evidence indicates that in response to an 
external stress, an intracellular kinase cascade becomes rap- 
idly activated. This kinase cascade includes mitogen-acti- 
vated protein (MAP) kinases, MAP kinase kinases and 
MAP kinase kinase kinases. Three distinct MAP kinases 
have been identified: the ERK group, the JNK/SAPK group, 
and the p38 MAP kinase isoform, of which the latter can 
activate MAPKAP kinase 2 by phosphorylation [22]. The pre- 
cise physiological role of MAPKAP kinase 2 is not known, 
but this kinase has been implicated as a downstream olecule 
of the stress-activated protein kinase cascade. It has been 
shown that except for MAPKAP kinase 2, no other kinases 
including protein kinase C are capable of inducing phospho- 
rylation of HSP 27 directly [24]. Induction of the expression of 
HSP 27 in response to diverse stresses has been demonstrated. 
For example, both ischemia/reperfusion a d oxidative stress 
can induce the expression of HSP 27 in mammalian hearts 
[25]. The facts that phosphorylation of HSP 27 precedes its 
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Fig. 4. Effects of preconditioning and genistcin on PKC in rat heart. 
Isolated hearts were perfused with 100 pM genistein for 10 min 
prior to preconditioning by repeated ischemia nd reperfusion. The 
control group did not receive any genistein. After preconditioning, 
hearts were subjected to 30 rain of ischemia followed by 30 rain of 
reperfusion. Hearts were homogenized and particulate and cytosolic 
fractions were prepared by differential centrifugation. PKC was as- 
sayed in both particulate and cytosolic fractions. Results are ex- 
pressed as means + S.E.M. of six animals per group. Each assay was 
run in duplicate. *P<0.05 compared to control; **P<0.05 com- 
pared to baseline control; ***P<0.05 compared to preconditioned 
group. C: control; CG: control+ genistein; PC: preconditioned; G: 
preconditioned+genistein. Black columns, cytosolic fraction; 
stippled columns, particulate fraction. 
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activation [26] and HSP 27 is induced in response to stress 
including ischemic preconditioning and implicated in myocar- 
dial preservation [14], suggest a role of MAPKAP kinase 2 in 
ischemic preconditioning and myocardial adaptation. 
Although our understanding of myocardial adaptation to 
stress is far from complete, it is believed that such adaptation 
occurs in two distinct phases: early adaptation also known as 
preconditioning, a rapid short-lived phenomenon likely to be 
mediated by the signal transduction process; and late adapta- 
tion, believed to occur by the regulation of gene expression 
[27]. The results of this study indicate that ischemic precondi- 
tioning rapidly activates the tyrosine kinase-phospholipase D 
signaling pathway resulting in the activation of protein kinase 
C, MAP kinases and MAPKAP kinase 2. Very recently, we 
have demonstrated that a variety of stresses can rapidly acti- 
vate MAPKAP kinase 2 which in turn can induce heat shock 
proteins in myocardial cells (Zu, Ai, Gilchrist, Sha'afi, Das 
and Huang, personal communication). Activation of heat 
shock proteins has been shown to be instrumental for the 
adaptation of the heart to ischemic stress [25]. It is tempting 
to speculate that activation of MAPKAP kinase 2 may be the 
cellular link between preconditioning (early adaptation) and 
ultimate adaptation. 
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